Clinical trials: Antipsychotics
Off-label Use of Atypical Antipsychotic Drugs
iADAPT: Off Label Use of Antipsychotics in the Nursing Home
The investigators propose to evaluate the effectiveness of 3 different methods to promote the dissemination and adoption of evidenced-based review guides into the nursing home setting.
- Trial name
- NCT01347619
- Testing
- Toolkit only with Web Access to Online Version, Toolkit, Periodic Audit/Feedback, Educational Messages, Items in Arm 2 plus Academic Detailing Program
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia or Schizoaffective Disorder
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
- Trial name
- MAD (NCT02504476)
- Testing
- AMG 581, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia
A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
The purpose of this study is to evaluate the pharmacokinetics of 2 extended-release (ER) formulations of 2 mg-eq paliperidone in comparison to the 2 mg immediate-release (IR) paliperidone oral solution and to evaluate the effect…
- Trial name
- NCT00796471
- Testing
- Paliperidone ER
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Hepatic Impairment
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate release (IR) paliperidone, after oral administration, in patients having moderate hepatic impairment compared to patients having normal…
- Trial name
- NCT00791284
- Testing
- Intermediate release (IR) Paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Insulin Resistance, Dyslipidemia
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this…
- Trial name
- NCT00625170
- Testing
- olanzapine, Haloperidol
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Hyperglycemia, Hyperlipidemia
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Primary Aim: To test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates…
- Trial name
- NCT00910988
- Testing
- Olanzapine, Ziprasidone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Psychosis
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
- Trial name
- NCT01720095
- Testing
- Niaspan
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Normal Non-fluency
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
Within the past 20 years, there has been a striking increase in the incidence of obesity 1;2, type 2 diabetes mellitus (T2DM) 3-5, and cardiovascular diseases (CVD) in the schizophrenic population 6-8 .
- Trial name
- NCT02447835
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Michael Rickels
Normal Volunteers
Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
The aim of the study is to investigate the negative symptoms and cognitive function after administration of antipsychotics in healthy volunteer.
- Trial name
- NCT01185418
- Testing
- risperidone, aripiprazole, haloperidol
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia, Diabetes
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine.
- Conditions
- Schizophrenia, Diabetes, Insulin Resistance
- Trial name
- NCT01160991
- Testing
- Glucose clamp technique, Amisulpride, Olanzapine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia
The purpose of this study is to evaluate abnormal dopamine synthesis and connectivity according to the antipsychotic treatment response in schizophrenia.
- Trial name
- NCT02248987
- Testing
- patients treated with antipsychotics
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
The aberrant expression of micro-RNAs (miRNAs) has been described in many human diseases, including schizophrenia (SZ). The previous work has indicated a strong genetic association between the miRNA-30e precursor (pre-miR-30e)…
- Trial name
- NCT02650102
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanxi Medical University
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Schizophreniform
Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment
The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic amino acids, in patients with First Psychotic Episode (FPE).
- Conditions
- Schizophrenia, Schizophreniform, Schizoaffective Disorder, Brief Psychotic Episode
- Trial name
- NCT00789022
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Pregnant Women, Psychotropic Drugs
National Pregnancy Registry for Psychiatric Medications
The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many…
- Trial name
- NCT01246765
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- NCT00207064
- Testing
- quetiapine
- Where
- 3 sites in Denmark
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia
A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone
The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.
- Trial name
- NCT00796432
- Testing
- OROS paliperidone
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
- Trial name
- NCT02536846
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Dost Ongur
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago